Teva Pharmaceutical Industries Ltd., an Israeli drug maker with U.S. headquarters in North Wales, reported today that a Phase 3 clinical trial showed that its experimental oral multiple sclerosis drug laquinimod reduced relapses of the disease.

The same study showed that the drug also slowed the progression of disabilities brought on by MS.

Teva, which primarily has been a maker of generic drugs, expects detailed results of the trial to be presented in the first half of 2011. A second study of the drug is ongoing. Its results are expected in the third quarter of 2011. In addition, Teva is studying the drug's effects on Crohn's disease and Lupus.

The U.S. Food and Drug Administration granted the drug fast-track designation in February 2009, which results in possible faster review and approval.    - Christopher K. Hepp